JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

AstraZeneca PLC ADR

Fechado

73.59 -1.31

Visão Geral

Variação de preço das ações

24h

Atual

Mín

73.52

Máximo

73.74

Indicadores-chave

By Trading Economics

Rendimento

-923M

2.5B

Vendas

1B

15B

P/E

Médio do Setor

27.832

34.393

Rendimento de Dividendos

2.12

Margem de lucro

16.947

Funcionários

94,300

EBITDA

-18M

5B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+26.44% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

2.12%

2.54%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.1B

231B

Abertura anterior

74.9

Fecho anterior

73.59

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

AstraZeneca PLC ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

29 de jul. de 2025, 08:08 UTC

Ganhos

AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth -- Update

29 de jul. de 2025, 06:46 UTC

Ganhos

AstraZeneca Books Record Quarterly Revenue as Oncology Boosts Growth

8 de ago. de 2025, 10:51 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

1 de ago. de 2025, 11:10 UTC

Ações em Alta

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

29 de jul. de 2025, 11:02 UTC

Ganhos

AstraZeneca 2Q Adj EPS $2.17 >AZN.LN

29 de jul. de 2025, 11:02 UTC

Ganhos

AstraZeneca 2Q EPS $1.58 >AZN.LN

29 de jul. de 2025, 11:01 UTC

Ganhos

AstraZeneca 2Q Rev $14.5B >AZN.LN

29 de jul. de 2025, 11:00 UTC

Ganhos

AstraZeneca Results: H1 and Q2 2025

29 de jul. de 2025, 08:00 UTC

Conversa de Mercado
Ganhos

AstraZeneca Holding Back on a Guidance Upgrade Disappoints -- Market Talk

29 de jul. de 2025, 07:53 UTC

Conversa de Mercado
Ganhos

AstraZeneca Continues to Deliver Under U.S. Tariff Threat -- Market Talk

29 de jul. de 2025, 07:26 UTC

Conversa de Mercado
Ganhos

AstraZeneca Shares Look Undervalued -- Market Talk

29 de jul. de 2025, 06:03 UTC

Ganhos

Analysts Saw AstraZeneca 2Q Total Revenue at $14.15B

29 de jul. de 2025, 06:03 UTC

Ganhos

AstraZeneca 2Q Total Revenue $14.46B

29 de jul. de 2025, 06:03 UTC

Ganhos

Analysts Saw AstraZeneca 2Q Core EPS at $2.16

29 de jul. de 2025, 06:03 UTC

Ganhos

AstraZeneca 2Q Core EPS $2.17

29 de jul. de 2025, 06:02 UTC

Ganhos

AstraZeneca Sees Core EPS Increasing by a Low Double-Digit Percentage

29 de jul. de 2025, 06:02 UTC

Ganhos

AstraZeneca Sees Total Revenue Increasing by a High Single-Digit Percentage

29 de jul. de 2025, 06:02 UTC

Ganhos

AstraZeneca Backs 2025 View

29 de jul. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 2Q Rev $14.46B

29 de jul. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 2Q Adj EPS $2.17

29 de jul. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 2Q Pretax Pft $3.13B

29 de jul. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 2Q Net Pft $2.45B

29 de jul. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 2Q Oper Pft $3.51B

29 de jul. de 2025, 06:00 UTC

Ganhos

AstraZeneca PLC 2Q EPS $1.57

28 de jul. de 2025, 10:51 UTC

Conversa de Mercado

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

22 de jul. de 2025, 10:19 UTC

Conversa de Mercado

AstraZeneca's Big U.S. Spending Plans Could Put NY Listing on the Table -- Market Talk

22 de jul. de 2025, 09:34 UTC

Ações em Alta

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

9 de jul. de 2025, 10:59 UTC

Conversa de Mercado

Pharma Companies Would Be Severely Hurt by 200% Tariff -- Market Talk

9 de jul. de 2025, 09:17 UTC

Ações em Alta

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New -2-

Comparação entre Pares

Variação de preço

AstraZeneca PLC ADR Previsão

Preço-alvo

By TipRanks

26.44% parte superior

Previsão para 12 meses

Média 93 USD  26.44%

Máximo 97 USD

Mínimo 85 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para AstraZeneca PLC ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 69.55Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.